Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

NCT ID: NCT00052936

Last Updated: 2021-05-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 1506 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2001-01-31
• Study Completion Date: 2010-08-05

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy is more effective with or without rituximab in treating aggressive non-Hodgkin's lymphoma.

PURPOSE: This randomized phase III trial is studying how well giving cyclophosphamide, doxorubicin, vincristine, and prednisone together with or without rituximab works in treating older patients who have aggressive non-Hodgkin's lymphoma. (This trial is no longer randomized as of 6/2005).

Detailed Description

OBJECTIVES:

Primary

• Compare the efficacy of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with vs without rituximab in elderly patients with aggressive non-Hodgkin's lymphoma.
• Compare the efficacy of 6 vs 8 courses of CHOP chemotherapy in patients treated with these regimens.
• Compare the rate of complete remission, rate of primary progression, tumor control, disease-free survival, overall survival, and relapse after radiotherapy in patients treated with these regimens.
• Compare the safety and side effects of these regimens in these patients.

Secondary

• Compare short-term and long-term side effects of these regimens in these patients.
• Compare quality of life of patients treated with these regimens.
• Compare the cost of these regimens in these patients.
• Determine relapse in patients treated with these regimens who received involved-field radiotherapy.

OUTLINE: This is a randomized (randomized part of study completed as of 6/2005), open-label, multicenter study. Patients are stratified according to participating center, value for serum lactic dehydrogenase (no greater than upper limit of normal [ULN] vs greater than ULN), bulky disease present (no vs yes), stage (I or II vs III or IV), general ECOG status of patient (0 or 1 vs 2), and age (61 to 70 vs 71-80). Patients are randomized to 1 of 4 treatment arms. Patients with CD20-negative lymphoma are randomized to arms I or II only.

• Prephase treatment:Patients receive vincristine IV on day -6 and prednisone on day -6 to day 0 before initiating CHOP chemotherapy.
• Arm I (closed to accrual as of 7/25/2005): Patients receive standard CHOP chemotherapy comprising cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1 and oral prednisone on days 1-5. Patients also receive filgrastim (G-CSF) subcutaneously once daily on days 6-12 of each CHOP course. Treatment repeats every 2 weeks for 6 courses.
• Arm II (closed to accrual as of 7/25/2005): Patients receive standard CHOP chemotherapy and G-CSF as in arm I for a total of 8 courses.
• Arm III: Patients receive standard CHOP chemotherapy and G-CSF as in arm I. Patients also receive rituximab IV before CHOP every 2 weeks for a total of 8 courses.
• Arm IV (closed to accrual as of 7/25/2005): Patients receive standard CHOP chemotherapy and G-CSF as in arm II. Patients also receive rituximab IV before CHOP every 2 weeks for a total of 8 courses.

In all arms, treatment continues in the absence of disease progression or unacceptable toxicity.

Beginning 3-6 weeks after completion of the last chemotherapy course, after complete recovery of bone marrow, and after complete remision of mucositis, patients with sites of initial bulky disease or extranodal involvement undergo radiotherapy 5 times a week for 4 weeks.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: Approximately 1580 patients will be accrued for this study within 5 years.

Conditions

Lymphoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

S6

6x CHOP-14

Group Type: EXPERIMENTAL

filgrastim

Intervention Type: BIOLOGICAL

CHOP regimen

Intervention Type: DRUG

cyclophosphamide

Intervention Type: DRUG

doxorubicin hydrochloride

Intervention Type: DRUG

prednisone

Intervention Type: DRUG

vincristine sulfate

Intervention Type: DRUG

radiation therapy

Intervention Type: RADIATION

36Gy on BULK and extranodal involvement

R6

6x CHOP-14 + 8x Rituximab

Group Type: EXPERIMENTAL

filgrastim

Intervention Type: BIOLOGICAL

rituximab

Intervention Type: BIOLOGICAL

CHOP regimen

Intervention Type: DRUG

cyclophosphamide

Intervention Type: DRUG

doxorubicin hydrochloride

Intervention Type: DRUG

prednisone

Intervention Type: DRUG

vincristine sulfate

Intervention Type: DRUG

radiation therapy

Intervention Type: RADIATION

36Gy on BULK and extranodal involvement

S8

8x CHOP-14

Group Type: EXPERIMENTAL

filgrastim

Intervention Type: BIOLOGICAL

CHOP regimen

Intervention Type: DRUG

cyclophosphamide

Intervention Type: DRUG

doxorubicin hydrochloride

Intervention Type: DRUG

prednisone

Intervention Type: DRUG

vincristine sulfate

Intervention Type: DRUG

radiation therapy

Intervention Type: RADIATION

36Gy on BULK and extranodal involvement

R8

8x CHOP-14 + 8x Rituximab

Group Type: EXPERIMENTAL

filgrastim

Intervention Type: BIOLOGICAL

rituximab

Intervention Type: BIOLOGICAL

CHOP regimen

Intervention Type: DRUG

cyclophosphamide

Intervention Type: DRUG

doxorubicin hydrochloride

Intervention Type: DRUG

prednisone

Intervention Type: DRUG

vincristine sulfate

Intervention Type: DRUG

radiation therapy

Intervention Type: RADIATION

36Gy on BULK and extranodal involvement

Interventions

filgrastim

Intervention Type: BIOLOGICAL

rituximab

Intervention Type: BIOLOGICAL

CHOP regimen

Intervention Type: DRUG

cyclophosphamide

Intervention Type: DRUG

doxorubicin hydrochloride

Intervention Type: DRUG

prednisone

Intervention Type: DRUG

vincristine sulfate

Intervention Type: DRUG

radiation therapy

36Gy on BULK and extranodal involvement

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed aggressive non-Hodgkin's lymphoma (NHL) by an excisional biopsy of a lymph node or an extensive biopsy of an extranodal involvement (if there is no lymph node involvement)
• CD20^+ B-cell lymphoma or CD20^- B-cell and T-cell lymphoma allowed
• B-cell NHL including the following:

• Stage III follicular lymphoma
• Stage III follicular lymphoma and diffuse B-cell lymphoma
• Lymphoblastic precursor B-cell lymphoma
• Diffuse large cell B-cell lymphoma

• Centroblastic
• Immunoblastic
• Plasmablastic
• Anaplastic large cell
• T-cell-rich B-cell lymphoma
• Primary effusion lymphoma
• Intravasal B-cell lymphoma
• Primary mediastinal B-cell lymphoma
• Mantle zone lymphoma, blastoid
• Burkitt's lymphoma
• Burkitt-like lymphoma
• Aggressive marginal zone lymphoma (monocytoid)
• T-cell NHL including the following:

• Lymphoblastic precursor T-cell lymphoma
• Peripheral T-cell lymphoma (PTCL) not otherwise specified (NOS)

• Lennert's lymphoma
• T-zone lymphoma
• T-cell lymphoma of the angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) type
• Anaplastic large cell lymphoma

• ALK^+
• ALK^-
• Extranodal NK/T-cell lymphoma, nasal type
• Intestinal T/NK-cell lymphoma (with or without enteropathy)

• Hepatosplenic gamma-delta lymphoma
• Subcutaneous panniculitis-like PTCL
• Aggressive T/NK PTCL
• Anaplastic large-cell NHL, NOS
• Bone marrow involvement no more than 25%
• No lymphoma that is clearly restricted to the CNS or originating from the gastrointestinal tract

PATIENT CHARACTERISTICS:

Age

• 61 to 80

Performance status

• ECOG 0-2 OR
• Karnofsky 60-100%

Life expectancy

• Not specified

Hematopoietic

• WBC at least 2,500/mm^3
• Platelet count at least 100,000/mm^3

Hepatic

• Bilirubin no greater than 2 times upper limit of normal (ULN)
• No active hepatitis infection

Renal

• Creatinine no greater than 2 times ULN

Cardiovascular

• No Canadian Cardiovascular Society class III or IV angina pectoris
• No New York Heart Association class III or IV cardiac failure
• Ejection fraction at least 50%
• Fractional shortenings at least 25% by echocardiography or nuclear medicine examination

Pulmonary

• FEV1 at least 50%
• Diffusion capacity at least 50%

Other

• No uncontrolled diabetes mellitus
• No known hypersensitivity to any study medications
• No other concurrent malignancy
• HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• No prior chemotherapy

Endocrine therapy

• Not specified

Radiotherapy

• No prior radiotherapy

Surgery

• Not specified

Other

• Must not have already initiated lymphoma therapy (except for the prephase treatment specified for this study)
• No other concurrent lymphoma therapy
• No concurrent participation in another treatment study

• Minimum Eligible Age: 61 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

German High-Grade Non-Hodgkin's Lymphoma Study Group

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael G.M. Pfreundschuh, MD

Role: STUDY_CHAIR

Universitaetsklinikum des Saarlandes

Locations

Haematologisch Onkologische Praxis

Aachen, , Germany

Klinikum St. Marien

Amberg, , Germany

Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie

Ansbach, , Germany

II. Medizinische Klinik

Aschaffenburg, , Germany

Specialist Practice for Oncology

Aschaffenburg, , Germany

Haematologische Praxis

Augsburg, , Germany

Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg

Augsburg, , Germany

Klinikum Augsburg

Augsburg, , Germany

Kreiskrankenhaus Aurich

Aurich, , Germany

Regional Hospital Bad Hersfeld

Bad Hersfeld, , Germany

Humaine - Clinic

Bad Saarow, , Germany

Krankenhaus Hohe Warte Mediziniche Klinik

Bayreuth, , Germany

Robert Roessle Comprehensive Cancer Center - Charite Campus Buch

Berlin, , Germany

Haematologisch-Onkologische Schwerpunktpraxis

Berlin, , Germany

Hospital Complex Bernburg

Bernburg, , Germany

Krankenhaus Bietigheim

Bietigheim, , Germany

Saint Agnes Hospital

Bocholt, , Germany

Saint Josef Hospital

Bochum, , Germany

Knappschaft Krankenhaus

Bochum, , Germany

Medizinische Poliklinik

Bonn, , Germany

Rheinische Friedrich-Wilhelms-Universitat

Bonn, , Germany

DIAKO Ev. Diakonie Krankenhaus gGmbH

Bremen, , Germany

Medizinische Klinik Am Lukas - Krankenhaus

Bünde, , Germany

General Hospital

Celle, , Germany

Hospital Kuchwald Chemnitz

Chemnitz, , Germany

Praxis Fuer Haematologie Internistische Onkologie

Cologne, , Germany

Medizinische Universitaetsklinik I at the University of Cologne

Cologne, , Germany

Cologne-Kalk, , Germany

Lung Clinic Cologne-Merheim

Cologne-Merheim, , Germany

Carl - Thiem - Klinkum Cottbus

Cottbus, , Germany

Klinikum Darmstadt

Darmstadt, , Germany

Saint Johannes Hospital Dortmund

Dortmund, , Germany

Universitatsklinikum Carl Gustav Carus

Dresden, , Germany

St. Johannes Hospital - Medical Klinik II

Duisburg, , Germany

Franz Hospital Dulmen

Dülmen, , Germany

Florence-Nightingale-Krankenhause, Deaconess Kaiserswerth

Düsseldorf, , Germany

Hans - Susemihl - Krankenhaus

Emden, , Germany

Klinikum Erfurt

Erfurt, , Germany

St. Antonius Hospital

Eschweiler, , Germany

Universitaetsklinikum Essen

Essen, , Germany

Krankenhaus Nordwest

Frankfurt, , Germany

Klinikum Frankfurt (Oder) GmbH

Frankfurt (Oder), , Germany

Evang. Deaconess Hospital Freiburg

Freiburg im Breisgau, , Germany

Municipal Hospital Complex

Fulda, , Germany

Robert - Koch Hospital

Gehrden, , Germany

Centre for Internal Medicine Gieben

Giessen, , Germany

Universitaetsklinikum Goettingen

Göttingen, , Germany

Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet

Greifswald, , Germany

Staedtisches Klinikum Guetersloh

Gütersloh, , Germany

Allgemeines Krankenhaus Hagen

Hagen, , Germany

St. Marien Hospital - Katholisches Krankenhaus Hagen gGmbH

Hagen, , Germany

Krankenhaus St. Elisabeth und St. Barbara

Halle, , Germany

Krankenhaus Martha-Maria Halle-Doelau gGmbH

Halle, , Germany

Universitaetsklinikum Halle

Halle, , Germany

Hamburg, , Germany

University Medical Center Hamburg - Eppendorf

Hamburg, , Germany

Asklepios Klinik Nord Heidberg

Hamburg, , Germany

Allgemeines Krankenhaus Altona

Hamburg, , Germany

Haematologisch-Onkologische Praxis Altona

Hamburg, , Germany

Evangelische Krankenhaus Hamm

Hamm, , Germany

Hanover, , Germany

Henriettenstiftung Krankenhaus

Hanover, , Germany

Krankenhaus Siloah - Medizinische Klinik II

Hanover, , Germany

Medizinische Hochschule Hannover

Hanover, , Germany

Oncology Specialists Clinic

Harrislee, , Germany

Thoraxklinik Heidelberg

Heidelberg, , Germany

Medizinische Universitaetsklinik und Poliklinik

Heidelberg, , Germany

Regional Hospital Heidenheim

Heidenheim, , Germany

Regional Hospital Am Plattenwald - Bad Friedrichshall

Heilbronn, , Germany

Klinikum Herford

Herford, , Germany

Marienhospital at Ruhr University Bochum

Herne, , Germany

Privatklinik Dr. R. Schindlbeck GmbH & Co. KG

Herrsching am Ammersee, , Germany

Onkologische Schwerpunktpraxis

Hildesheim, , Germany

Evang. Hospital

Holzminden, , Germany

Medical University Hospital Homburg

Homburg, , Germany

Hospital Complex Hoyerswerda

Hoyerswerda, , Germany

Gemeinschaftspraxis Innere Medizin

Jena, , Germany

Klinikum der Friedrich-Schiller Universitaet Jena

Jena, , Germany

Municipal Hospital Complex of the University

Kaiserslautern, , Germany

Staedtisches Klinikum Karlsruhe gGmbH

Karlsruhe, , Germany

Red Cross Hospital Kassel

Kassel, , Germany

Staedtisches Krankenhaus Kiel

Kiel, , Germany

Stiftungsklinikum Mittelrhein - Gesundheitszentrum Evangelisches Stift Sankt Martin Koblenz gGmbH

Koblenz, , Germany

Praxis fuer Haematologie und Onkologie

Koblenz, , Germany

Leonardis Clinic

Kornwestheim, , Germany

Klinikum Krefeld GmbH

Krefeld, , Germany

Frankenwald Klinik

Kronach, , Germany

Caritas - Krakenhaus Lebach

Lebach, , Germany

University Leipzig Clinic of Internal Medicine

Leipzig, , Germany

Klinikum "St. Georg" Leipzig

Leipzig, , Germany

Leipzig, , Germany

Klinikum Lippe - Lemgo

Lemgo, , Germany

St. Vincenz Hospital Limburg

Limburg, , Germany

St. Bonifatius Hospital Lingen

Lingen, , Germany

Dreifaltigkeits Hospital

Lippstadt, , Germany

Klinikum Ludwigsburg

Ludwigsburg, , Germany

St. Marien Hospital Ludwighafen

Ludwigshafen, , Germany

Municipal Complex of Ludwigshafen

Ludwigshafen, , Germany

Universitaetsklinikum Schleswig-Holstein - Campus Luebeck

Lübeck, , Germany

Staedtisches Klinikum Magdeburg - Altstadt

Magdeburg, , Germany

Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg

Magdeburg, , Germany

Johannes Gutenberg University

Mainz, , Germany

III Medizinische Klinik Mannheim

Mannheim, , Germany

Marburg, , Germany

Universitaetsklinikum Giessen und Marburg GmbH - Marburg

Marburg, , Germany

Regional Hospital Mayen

Mayen, , Germany

Klinikum Minden

Minden, , Germany

Minden, , Germany

Monchenglasbach/Rheydt, , Germany

Ev. Hospital Bethesda

Mönchengladbach, , Germany

Hospital Maria-Hilf II

Mönchengladbach, , Germany

Munich Oncologic Practice at Elisenhof

Munich, , Germany

Klinikum der Universitaet Muenchen - Innenstadt Campus

Munich, , Germany

Krankenhaus Muenchen Schwabing

Munich, , Germany

Klinikum der Universitaet Muenchen - Grosshadern Campus

Munich, , Germany

Municipal Hospital Munich

Munich, , Germany

Evangelisches Krankenhaus - Mulheim

Mülheim, , Germany

St. Marien Hospital - Muelheim an der Ruhr

Mülheim, , Germany

Kreiskrankenhaus Muenchberg

Münchberg, , Germany

Medizinische Klinik und Poliklinik A - Universitaetsklinikum Muenster

Münster, , Germany

Regional Hospital Neumarkt

Neumarkt, , Germany

Staedtisches Klinikum Neunkirchen gGmbH

Neunkirchen, , Germany

Lukaskrankenhaus Neuss

Neuss, , Germany

Klinikum Nuernberg - Klinikum Nord

Nuremberg, , Germany

Klinikum Offenburg

Offenburg, , Germany

Hematologische Praxis

Oldenburg, , Germany

Ev. Hospital Oldenburg

Oldenburg, , Germany

Klinikum Oldenburg

Oldenburg, , Germany

Paracelsus - Klinik Osnabrueck

Osnabrück, , Germany

Municipal Hospital Complex

Pforzheim, , Germany

Klinikum Ernst Von Bergmann

Potsdam, , Germany

Kreiskrankenhaus Radebeul

Radebeul, , Germany

Krankenhaus St. Elisabeth - Ravensburg

Ravensburg, , Germany

Klinikum der Universitaet Regensburg

Regensburg, , Germany

Hematologische Onkologische Praxis

Regensburg, , Germany

Krankenhaus Barmherzige Brueder Regensburg

Regensburg, , Germany

Jakobi Krankenhaus

Rheine, , Germany

Klinik und Poliklinik fuer Innere Medizin - Universitaet Rostock

Rostock, , Germany

Klinik und Poliklinik fuer Strahlentherapie - Universitaetsklinikum Rostock

Rostock, , Germany

Rostock, , Germany

Caritasklinik St. Theresia

Saarbrücken, , Germany

Schwerpunktpraxis fuer Haematologie und Onkologie

Saarbrücken, , Germany

St. Elizabeth-Klinik Saarlouis

Saarlouis, , Germany

Martin - Luther Hospital

Schleswig, , Germany

Deaconess Hospital

Schwäbisch Hall, , Germany

Leopoldina - Krankenhaus

Schweinfurt, , Germany

Evang. Jung-Stilling Hospital

Siegen, , Germany

St. Lukas - Clinic Solingen

Solingen, , Germany

Klinik fuer Onkologie - Katharinenhospital Stuttgart

Stuttgart, , Germany

Diakonie Klinikum Stuttgart

Stuttgart, , Germany

Klinikum Stuttgart - Buergerhospital

Stuttgart, , Germany

Hospital Bad Cannstatt

Stuttgart, , Germany

Robert-Bosch-Krankenhaus

Stuttgart, , Germany

St. Elisabeth Hospital Thuine

Thuine, , Germany

Regional Hospital Traunstein

Traunstein, , Germany

Krankenanstalt Mutterhaus der Borromaerinnen

Trier, , Germany

Trier, , Germany

Krankenhaus Barmherzigen Brueder

Trier, , Germany

Hospital Tutzing

Tutzing, , Germany

Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm

Ulm, , Germany

Ev. Hospital Unna

Unna, , Germany

St. Marienhospital - Vechta

Vechta, , Germany

Municipal Hospital Complex

Villingen-Schwenningen, , Germany

Regional Hospital Waldbrol

Waldbröl, , Germany

Evangelisches Krankenhaus Essen Werden

Werden, , Germany

Hospital Wetzler

Wetzlar, , Germany

Deutsche Klinik fuer Diagnostik

Wiesbaden, , Germany

Dr. Horst-Schmidt-Kliniken

Wiesbaden, , Germany

Ev. Hospital Witten-Herdecke

Witten, , Germany

Kliniken St. Antonius

Wuppertal, , Germany

University Wurzburg

Würzburg, , Germany

Municipal Hospital Complex Zwickau

Zwickau, , Germany

City Hospital Triemli

Zurich, , Switzerland

UniversitaetsSpital Zuerich

Zurich, , Switzerland

Countries

Germany; Switzerland

References

Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trumper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008 Feb;9(2):105-16. doi: 10.1016/S1470-2045(08)70002-0. Epub 2008 Jan 15.

Reference Type: RESULT

PMID: 18226581 (View on PubMed)

Christofyllakis K, Kaddu-Mulindwa D, Lesan V, Rixecker T, Kos IA, Held G, Regitz E, Pfreundschuh M, Bittenbring JT, Thurner L, Poeschel V, Ziepert M, Altmann B, Bewarder M. An inherited genetic variant of the CEP72 gene is associated with the development of vincristine-induced peripheral neuropathy in female patients with aggressive B-cell lymphoma. Ann Hematol. 2024 Nov;103(11):4599-4606. doi: 10.1007/s00277-024-05973-9. Epub 2024 Sep 4.

Reference Type: DERIVED

PMID: 39227453 (View on PubMed)

Kuhnl A, Cunningham D, Counsell N, Hawkes EA, Qian W, Smith P, Chadwick N, Lawrie A, Mouncey P, Jack A, Pocock C, Ardeshna KM, Radford J, McMillan A, Davies J, Turner D, Kruger A, Johnson PW, Gambell J, Rosenwald A, Ott G, Horn H, Ziepert M, Pfreundschuh M, Linch D. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial. Ann Oncol. 2017 Jul 1;28(7):1540-1546. doi: 10.1093/annonc/mdx128.

Reference Type: DERIVED

PMID: 28398499 (View on PubMed)

Pfreundschuh M, Poeschel V, Zeynalova S, Hanel M, Held G, Schmitz N, Viardot A, Dreyling MH, Hallek M, Mueller C, Wiesen MH, Witzens-Harig M, Truemper L, Keller U, Rixecker T, Zwick C, Murawski N. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. J Clin Oncol. 2014 Dec 20;32(36):4127-33. doi: 10.1200/JCO.2013.54.6861. Epub 2014 Nov 17.

Reference Type: DERIVED

PMID: 25403207 (View on PubMed)

Bittenbring JT, Neumann F, Altmann B, Achenbach M, Reichrath J, Ziepert M, Geisel J, Regitz E, Held G, Pfreundschuh M. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. J Clin Oncol. 2014 Oct 10;32(29):3242-8. doi: 10.1200/JCO.2013.53.4537. Epub 2014 Aug 18.

Reference Type: DERIVED

PMID: 25135997 (View on PubMed)

Held G, Murawski N, Ziepert M, Fleckenstein J, Poschel V, Zwick C, Bittenbring J, Hanel M, Wilhelm S, Schubert J, Schmitz N, Loffler M, Rube C, Pfreundschuh M. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014 Apr 10;32(11):1112-8. doi: 10.1200/JCO.2013.51.4505. Epub 2014 Feb 3.

Reference Type: DERIVED

PMID: 24493716 (View on PubMed)

Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, Klapper W, Hummel M, Stein H, Hansmann ML, Schmelter C, Moller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trumper L, Siebert R, Loeffler M, Rosenwald A, Ott G; German High-Grade Non-Hodgkin Lymphoma Study Group. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013 Mar 21;121(12):2253-63. doi: 10.1182/blood-2012-06-435842. Epub 2013 Jan 18.

Reference Type: DERIVED

PMID: 23335369 (View on PubMed)

Muller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, Wenger M, Nickenig C, Peter N, Lengfelder E, Metzner B, Rixecker T, Zwick C, Pfreundschuh M, Reiser M. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012 Apr 5;119(14):3276-84. doi: 10.1182/blood-2011-09-380949. Epub 2012 Feb 15.

Reference Type: DERIVED

PMID: 22337718 (View on PubMed)

Other Identifiers

DSHNHL-1999-1A

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

EU-20243

Identifier Type: OTHER

Identifier Source: secondary_id

CDR0000269015

Identifier Type: -

Identifier Source: org_study_id